CN108697700B - 氘代多潘立酮组合物和用于治疗病症的方法 - Google Patents

氘代多潘立酮组合物和用于治疗病症的方法 Download PDF

Info

Publication number
CN108697700B
CN108697700B CN201780008640.9A CN201780008640A CN108697700B CN 108697700 B CN108697700 B CN 108697700B CN 201780008640 A CN201780008640 A CN 201780008640A CN 108697700 B CN108697700 B CN 108697700B
Authority
CN
China
Prior art keywords
domperidone
active agent
release
formulation
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780008640.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN108697700A (zh
Inventor
凯瑟琳·皮尔斯
约恩·伊萨克松
皮约什·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinduomei Pharmaceutical Co Ltd
Original Assignee
Cinrx Pharma LLC
Xinduomei Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cinrx Pharma LLC, Xinduomei Pharmaceutical Co ltd filed Critical Cinrx Pharma LLC
Priority to CN202111078948.5A priority Critical patent/CN113995755A/zh
Publication of CN108697700A publication Critical patent/CN108697700A/zh
Application granted granted Critical
Publication of CN108697700B publication Critical patent/CN108697700B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780008640.9A 2016-02-04 2017-02-03 氘代多潘立酮组合物和用于治疗病症的方法 Active CN108697700B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111078948.5A CN113995755A (zh) 2016-02-04 2017-02-03 氘代多潘立酮组合物和用于治疗病症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291198P 2016-02-04 2016-02-04
US62/291,198 2016-02-04
PCT/US2017/016334 WO2017136617A1 (en) 2016-02-04 2017-02-03 Deuterated domperidone compositions and methods for therapy of disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111078948.5A Division CN113995755A (zh) 2016-02-04 2017-02-03 氘代多潘立酮组合物和用于治疗病症的方法

Publications (2)

Publication Number Publication Date
CN108697700A CN108697700A (zh) 2018-10-23
CN108697700B true CN108697700B (zh) 2021-08-17

Family

ID=59501077

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780008640.9A Active CN108697700B (zh) 2016-02-04 2017-02-03 氘代多潘立酮组合物和用于治疗病症的方法
CN202111078948.5A Pending CN113995755A (zh) 2016-02-04 2017-02-03 氘代多潘立酮组合物和用于治疗病症的方法
CN201880043378.6A Active CN111093653B (zh) 2016-02-04 2018-06-28 氘代多潘立酮组合物、方法和制备物
CN202310648870.9A Pending CN116712432A (zh) 2016-02-04 2018-06-28 氘代多潘立酮组合物、方法和制备物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202111078948.5A Pending CN113995755A (zh) 2016-02-04 2017-02-03 氘代多潘立酮组合物和用于治疗病症的方法
CN201880043378.6A Active CN111093653B (zh) 2016-02-04 2018-06-28 氘代多潘立酮组合物、方法和制备物
CN202310648870.9A Pending CN116712432A (zh) 2016-02-04 2018-06-28 氘代多潘立酮组合物、方法和制备物

Country Status (11)

Country Link
US (2) US10266516B2 (cg-RX-API-DMAC10.html)
EP (2) EP3411031B1 (cg-RX-API-DMAC10.html)
JP (3) JP7296185B2 (cg-RX-API-DMAC10.html)
KR (2) KR102851614B1 (cg-RX-API-DMAC10.html)
CN (4) CN108697700B (cg-RX-API-DMAC10.html)
AU (2) AU2017213852B2 (cg-RX-API-DMAC10.html)
BR (2) BR112018016032B1 (cg-RX-API-DMAC10.html)
CA (1) CA3055777A1 (cg-RX-API-DMAC10.html)
DK (2) DK3411031T3 (cg-RX-API-DMAC10.html)
EA (2) EA035515B1 (cg-RX-API-DMAC10.html)
WO (2) WO2017136617A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN108697700B (zh) * 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
US20210260055A1 (en) * 2018-06-21 2021-08-26 Dermavant Sciences GmbH Topical formulations of dgat1 inhibitors and their methods of use
KR20210082480A (ko) * 2018-10-25 2021-07-05 신돔 파마, 인크. 돔페리돈을 함유하는 제제
SG11202103284QA (en) * 2018-10-25 2021-05-28 Cindome Pharma Inc Formulations containing deuterated domperidone
US20220307004A1 (en) * 2021-03-29 2022-09-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Multi-Enzyme Nanoparticle-Assisted Stable Isotope Incorporation Into Small Molecules by Channeling
US20250268884A1 (en) * 2022-04-20 2025-08-28 Cindome Pharma, Inc. Deuterated Domperidone for Treating Gastroparesis
IL322534A (en) * 2023-03-23 2025-10-01 Cindome Pharma Inc Methods for treating diabetic gastroparesis

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
TW466119B (en) * 1994-02-28 2001-12-01 Janssen Pharmaceutica Nv Film coated tablet of paracetamol and domperidone
FR2725986B1 (fr) * 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20140070440A1 (en) 2001-10-12 2014-03-13 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140163060A1 (en) 2001-10-12 2014-06-12 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20130220526A1 (en) 2001-10-12 2013-08-29 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20160206639A9 (en) 2001-10-12 2016-07-21 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
CN1688294A (zh) 2002-10-01 2005-10-26 旗帜药物胶囊公司 用于制备软胶囊壁的肠溶组合物
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
CA2858733C (en) 2004-12-31 2017-12-19 Iceutica Pty Ltd Nanoparticle compositions and methods for synthesis thereof
ITMI20050477A1 (it) 2005-03-23 2006-09-24 Bouty S P A Cerotto transdermico
CN100435795C (zh) * 2006-02-27 2008-11-26 南京长澳医药科技有限公司 一种微粉化马来酸多潘立酮药物组合物及其制备方法
CN100386323C (zh) * 2006-02-27 2008-05-07 南京长澳医药科技有限公司 马来酸多潘立酮的合成方法
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
NZ573823A (en) 2006-06-30 2012-05-25 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CA2685362A1 (en) 2007-04-26 2008-11-06 Craig A. Aronchick Compositions and methods for transmucosal delivery of domperidone
MX2010001789A (es) 2007-08-15 2010-03-10 Mcneil Ppc Inc Regimen de dosificacion de ibuprofeno de liberacion inmediata y liberacion sostenida.
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090076010A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US20110160253A1 (en) 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
US20100113405A1 (en) * 2008-11-06 2010-05-06 Auspex Pharmaceuticals, Inc. Methylindazole modulators of 5-ht3 receptors
US20100120733A1 (en) * 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
NZ595985A (en) 2009-04-24 2014-07-25 Iceutica Pty Ltd A novel formulation of naproxen
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
CA2759123C (en) 2009-04-24 2019-01-15 Iceutica Pty Ltd Compositions of diclofenac acid with improved dissolution
MX360019B (es) 2009-04-24 2018-10-15 Iceutica Pty Ltd Una formulación novedosa de metaxalona.
US20140017299A1 (en) 2011-08-18 2014-01-16 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same
JP5093545B1 (ja) 2012-02-28 2012-12-12 ニチバン株式会社 貼付剤
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
ES2822375T3 (es) * 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US20140019395A1 (en) 2012-07-12 2014-01-16 Craig Charles Bauer Method and application of Fear, Love and Methodology as protocols within and of a programming group, as a means of creating an artificial individual, software system or other independent entity capable of independent self directive creation of choice and/or self directive creation of purpose within a virtual and/or any environment
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
US20140271787A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Continuous single layer film structure including discrete domains
TWI686212B (zh) 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
US20140272220A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Reduction in stress cracking of films
CN108697700B (zh) 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US11364226B2 (en) * 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
SG11202103284QA (en) * 2018-10-25 2021-05-28 Cindome Pharma Inc Formulations containing deuterated domperidone
US20250268884A1 (en) * 2022-04-20 2025-08-28 Cindome Pharma, Inc. Deuterated Domperidone for Treating Gastroparesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN CAS：1329614-18-7;STN-REGISTRY;《STN-REGISTRY》;20110907 *

Also Published As

Publication number Publication date
CN108697700A (zh) 2018-10-23
DK3644995T3 (da) 2025-08-18
CA3013123A1 (en) 2017-08-10
EA035515B1 (ru) 2020-06-29
CA3055777A1 (en) 2019-01-03
CN111093653B (zh) 2023-06-23
AU2017213852A1 (en) 2018-07-05
CN111093653A (zh) 2020-05-01
AU2018290905A1 (en) 2020-02-13
EP3411031A4 (en) 2019-08-07
EP3411031B1 (en) 2024-07-24
KR20180104662A (ko) 2018-09-21
US10266516B2 (en) 2019-04-23
WO2017136617A1 (en) 2017-08-10
KR102851614B1 (ko) 2025-08-29
JP7602324B2 (ja) 2024-12-18
EA201891727A1 (ru) 2018-12-28
EP3644995A1 (en) 2020-05-06
CN113995755A (zh) 2022-02-01
US20170298046A1 (en) 2017-10-19
BR112018016032B1 (pt) 2024-03-05
WO2019006078A1 (en) 2019-01-03
BR112019028185A8 (pt) 2020-08-11
EP3411031A1 (en) 2018-12-12
JP2023052045A (ja) 2023-04-11
US20190241543A1 (en) 2019-08-08
DK3411031T3 (da) 2024-10-21
KR20200044790A (ko) 2020-04-29
EP3644995B1 (en) 2025-05-07
BR112018016032A2 (pt) 2018-12-26
EA202090183A1 (ru) 2020-04-15
AU2018290905B2 (en) 2022-10-06
JP2019504068A (ja) 2019-02-14
KR102695402B1 (ko) 2024-08-16
JP2020534246A (ja) 2020-11-26
BR112019028185A2 (pt) 2020-07-07
WO2017136617A8 (en) 2017-10-05
JP7296185B2 (ja) 2023-06-22
AU2017213852B2 (en) 2021-04-08
US10590110B2 (en) 2020-03-17
CN116712432A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
US10590110B2 (en) Deuterated domperidone compositions, methods, and preparation
US11364226B2 (en) Deuterated domperidone compositions, methods, and preparation
CN101011393B (zh) 厄贝沙坦胃内滞留型缓释药物组合物
US12478612B2 (en) Deuterated domperidone compositions, methods, and preparation
HK40064919A (en) Deuterated domperidone compositions and methods for therapy of disorders
ES3034905T3 (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
CA3013123C (en) Deuterated domperidone compositions and methods for therapy of disorders
HK1259508A1 (en) Deuterated domperidone compositions and methods for therapy of disorders
HK40029064A (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
HK40029064B (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
HK1259508B (en) Deuterated domperidone compositions and methods for therapy of disorders
EA045546B1 (ru) Способ облегчения заболевания или состояния, связанного с моторикой желудочно-кишечного тракта, с использованием дейтерированного домперидона
HK40001556A (en) Deuterated domperidone compositions and methods for therapy of disorders
HK40001556B (en) Deuterated domperidone compositions and methods for therapy of disorders
BR112019016091B1 (pt) Unidade de dosagem oral e uso de floroglucinol e trimetilfloroglucinol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259508

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200512

Address after: Ohio, USA

Applicant after: Xinduomei Pharmaceutical Co., Ltd

Address before: Ohio, USA

Applicant before: CINRX PHARMA, LLC

GR01 Patent grant
GR01 Patent grant